Pembrolizumab shows modest, durable response in recurrent ovarian cancer
Click Here to Manage Email Alerts
In the KEYNOTE-100 study, presented during the ASCO2020 Virtual Scientific Program, Ursula A. Matulonis, MD, of Dana Farber Cancer Institute, showed pembrolizumab had a modest but durable impact on recurrent ovarian cancer.
“Pembrolizumab like other single-agent immune checkpoint inhibitors which have been studied in recurrent ovarian cancer, has modest activity in recurrent ovarian cancer. The activity of pembrolizumab appears to be higher in cancers that were CPS higher,” she told Healio. “The median duration of response – if there is a response it’s actually a pretty long response – 10.2 months.”
PDL-1 expression did seem to indicate the response rate, Matulonis said. Higher expression levels dictated greater response rate, which she said was similar to other KEYNOTE study results.
Collapse
Matulonis UA, et al. Abstract 6005. Presented at: ASCO20 Virtual Scientific Program; May 29-31, 2020.
Read more about
Click Here to Manage Email Alerts